Esperion will host a KOL event discussing LDL-cholesterol management and its implications for cardiovascular disease prevention.
Quiver AI Summary
Esperion has announced a virtual key opinion leader (KOL) event scheduled for January 9, 2025, to discuss the real-world application of its cholesterol-lowering medications, NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe). The event will feature LeAnne Bloedon, Esperion's VP of Clinical Development, and Patrick Moriarty, M.D., from the University of Kansas Medical Center. Participants can register for the webinar, which will be accessible via a live audio webcast on Esperion's website. Esperion is recognized as a commercial-stage biopharmaceutical company focused on addressing unmet patient needs in LDL-cholesterol management to combat cardiovascular disease, with products that have undergone extensive clinical trials. The company is also advancing its pipeline with new drug development initiatives.
Potential Positives
- Announcement of a virtual KOL event highlights Esperion's commitment to addressing unmet needs in LDL-cholesterol management and cardiovascular disease, showcasing its expertise in the field.
- Participation of a reputable expert, Dr. Patrick Moriarty, adds credibility to the company’s focus and the discussion of its products, emphasizing the importance of its medications in real-world settings.
- Emphasis on the FDA-approved NEXLETOL® and NEXLIZET® positions Esperion uniquely in the market as providers of non-statin treatments, addressing a significant segment of patients struggling with elevated LDL-C.
- Discussion of future development of ACLY inhibitors indicates ongoing innovation and potential for expansion in Esperion's product pipeline, suggesting long-term growth prospects for the company.
Potential Negatives
- The press release highlights an ongoing unmet need in LDL-cholesterol management, which could suggest that current treatments, including Esperion's products, may not be adequately addressing patient needs and expectations.
- Despite the support from the CLEAR Cardiovascular Outcomes Trial, the detail surrounding the trial may raise questions about the real-world efficacy and acceptance of NEXLETOL® and NEXLIZET® in clinical practice.
- The focus on a virtual KOL event may indicate limited in-person engagement with key opinion leaders, potentially reducing the impact of direct interactions that could enhance trust and credibility in their products.
FAQ
What is the focus of Esperion's upcoming KOL event?
The event will discuss the ongoing need for LDL-Cholesterol management to prevent cardiovascular disease.
Who will lead the KOL webinar for Esperion?
LeAnne Bloedon, VP and Head of Clinical Development at Esperion, will lead the webinar discussion.
How can I register for the KOL event?
You can find registration details on the Esperion website under the KOL webinar section.
What medications will be discussed during the KOL event?
The webinar will focus on the real-world use of NEXLETOL® and NEXLIZET® for LDL-C management.
Where can I access the KOL event replay?
The replay will be available on Esperion's website approximately two hours post-event and archived for about 90 days.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ESPR Insider Trading Activity
$ESPR insiders have traded $ESPR stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ESPR stock by insiders over the last 6 months:
- ERIC WARREN (Chief Commercial Officer) has traded it 6 times. They made 0 purchases and 6 sales, selling 5,465 shares.
- SHELDON L. KOENIG (President and CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 26,997 shares.
- BENJAMIN HALLADAY (Chief Financial Officer) sold 3,245 shares.
- JOANNE M. FOODY (Chief Medical Officer) sold 917 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ESPR Hedge Fund Activity
We have seen 79 institutional investors add shares of $ESPR stock to their portfolio, and 65 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP added 6,483,070 shares (+38.4%) to their portfolio in Q3 2024
- GREAT POINT PARTNERS LLC removed 5,791,594 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 3,110,402 shares (-47.7%) from their portfolio in Q3 2024
- WOODLINE PARTNERS LP removed 2,805,448 shares (-55.6%) from their portfolio in Q3 2024
- WHITEFORT CAPITAL MANAGEMENT, LP removed 2,299,121 shares (-100.0%) from their portfolio in Q3 2024
- VANGUARD GROUP INC added 2,226,315 shares (+20.6%) to their portfolio in Q3 2024
- CENTERBOOK PARTNERS LP added 1,543,126 shares (+98.3%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
– Leading Physician Expert to Discuss Continued Unmet Need in LDL-Cholesterol Management to Prevent Cardiovascular Disease –
ANN ARBOR, Mich., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL ® (bempedoic acid) and NEXLIZET ® (bempedoic acid and ezetimibe).
The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with:
-
Patrick Moriarty, M.D.
, Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas and Director of Clinical Pharmacology at the Atherosclerosis & Lipid-Apheresis Center.
Registration for the KOL webinar can be found here . A live audio webcast can be accessed on the investor and media section of the Esperion website . Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and esperionscience.com and follow Esperion on LinkedIn and X .
Esperion Contact Information:
Investors:
Alina Venezia
[email protected]
(734) 887-3903
Media:
Tiffany Aldrich
[email protected]
(616) 443-8438
